Compare ASTRAZENECA PHARMA with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SANOFI INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SANOFI INDIA ASTRAZENECA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 134.3 42.9 313.1% View Chart
P/BV x 37.7 8.7 431.8% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ASTRAZENECA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SANOFI INDIA
Dec-18
ASTRAZENECA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,2786,840 18.7%   
Low Rs8834,630 19.1%   
Sales per share (Unadj.) Rs228.41,203.1 19.0%  
Earnings per share (Unadj.) Rs10.4165.3 6.3%  
Cash flow per share (Unadj.) Rs16.3209.9 7.7%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs98.8963.6 10.3%  
Shares outstanding (eoy) m25.0023.03 108.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.8 99.2%   
Avg P/E ratio x104.234.7 300.4%  
P/CF ratio (eoy) x66.427.3 243.1%  
Price / Book Value ratio x10.96.0 183.8%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m27,008132,078 20.4%   
No. of employees `0001.43.3 41.1%   
Total wages/salary Rs m1,5354,068 37.7%   
Avg. sales/employee Rs Th4,210.98,393.8 50.2%   
Avg. wages/employee Rs Th1,132.21,232.4 91.9%   
Avg. net profit/employee Rs Th191.11,153.0 16.6%   
INCOME DATA
Net Sales Rs m5,71027,708 20.6%  
Other income Rs m123897 13.7%   
Total revenues Rs m5,83328,605 20.4%   
Gross profit Rs m4636,235 7.4%  
Depreciation Rs m1471,027 14.4%   
Interest Rs m07 0.0%   
Profit before tax Rs m4386,098 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,292 7.8%   
Profit after tax Rs m2593,806 6.8%  
Gross profit margin %8.122.5 36.0%  
Effective tax rate %40.837.6 108.7%   
Net profit margin %4.513.7 33.0%  
BALANCE SHEET DATA
Current assets Rs m3,20915,922 20.2%   
Current liabilities Rs m2,0706,235 33.2%   
Net working cap to sales %20.035.0 57.1%  
Current ratio x1.62.6 60.7%  
Inventory Days Days7264 113.7%  
Debtors Days Days3521 167.4%  
Net fixed assets Rs m7907,539 10.5%   
Share capital Rs m50230 21.7%   
"Free" reserves Rs m2,41921,962 11.0%   
Net worth Rs m2,46922,192 11.1%   
Long term debt Rs m00-   
Total assets Rs m4,60529,839 15.4%  
Interest coverage xNM872.1-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.9 133.5%   
Return on assets %5.612.8 44.0%  
Return on equity %10.517.2 61.2%  
Return on capital %17.727.5 64.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3007,587 3.9%   
Fx outflow Rs m2,0157,145 28.2%   
Net fx Rs m-1,715442 -388.1%   
CASH FLOW
From Operations Rs m883,739 2.4%  
From Investments Rs m-94-731 12.8%  
From Financial Activity Rs mNA-1,972 0.0%  
Net Cashflow Rs m-61,036 -0.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 15.7 14.6 107.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 15,184 84.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ABBOTT INDIA  NATCO PHARMA  DIVIS LABORATORIES  IPCA LABS  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - IPCA LABS COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS